Healthcare
Diagnostics Innovation Network
Preparing for a new era in genomics
Since the completion of the Human Genome Project in 2003, stakeholders across the US healthcare system—government, industry, patient organizations, and providers—have worked to advance precision medicine. Genomics offers many exciting Today, the possibilities, but it has its skeptics. The Diagnostics Innovation Network (DxIN) addresses the growth of genomics and its application for patients and consumers.
DxIN brings together, health and life insurers, genomics experts, industry players, and clinicians, to identify specific improvements that will enable genomics advance patient and consumer outcomes in the United States and other countries.
Project Background:
DxIN aims to continue the work initiated by the 2015 summit on genomics that emerged from the 2013-2015 SPOT/Dx working group. At the summit, SPOT/Dx stakeholders addressed the utility and value of integrating genomics and outcomes registries into clinical practice. In early 2017, leaders recognized the need to expand this pursuit and, in light of the growth of direct-to-consumer sequencing and the advent of data analytics, created DxIN to include consumer applications of genomics, as well as an ongoing focus on genomics in the clinic.
